Jazz Pharmaceuticals plc announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board. Dr. Love was the President and Chief Executive Officer of Global Blood Therapeutics Inc. from 2014 until its acquisition by Pfizer in 2023, where he led the company from a startup into a global commercial business with a pipeline of innovative therapies.
Previous leadership experience also has included Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals Inc. and President and Chief Executive Officer/Chairman of Nuvelo Inc. He started his biotech career at Genentech, Inc, holding several management positions. Dr. Love received a B.A. degree in molecular biology from Haverford College and his medical degree from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Dr. Love currently serves on the board of directors of Gilead Sciences, Royalty Pharma plc, and Structure Therapeutics Inc. As the Immediate Past Chair of the BIO Board of Directors, Dr. Love also brings deep expertise on biopharmaceutical public policy matters surrounding scientific innovation and patient access. Dr. Love's appointment reflects Jazz's ongoing focus on Board renewal with six of the Company's directors appointed in the past five years. Additionally, Kenneth O'Keefe has informed the Company of his intention to retire from the Jazz Board, effective December 1, 2025.
Mr. O'Keefe has served on the Jazz board since 2004, including as a valued member of the audit committee (which he chaired from 2012 to 2014). Mr. O'Keefe served as Managing Director and Chief Executive Officer of BPOC, LLC, a healthcare private equity firm he co-founded. He serves on the boards of several privately-held healthcare companies.
